Jon Burrows, CEO presents the HY results which are released on 28 June and updates on current performance at a webinar on 28 June at 12.30pm. There has been significant interest for the company's recently released Checkpoint Inhibitor Response Test from pharma companies, oncologists and healthcare administrators. CiRT has the potential to be a game changer for patients, oncologists and OBD and the positive early response is very encouraging.
The company recently attended the American Society of Clinical Oncology’s Annual conference with 46,000 participants in Chicago and were overwhelmed by the interest in the company and the EpiSwitch CiRT. There were significantly more meetings than anticipate and they have continued to receive enquiries post ASCO.
Register for the webinar here.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Register for the webinar here.
